A Phase 1 interventional study of Lucerastat and Placebo in Healthy Subjects, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study were to evaluate the safety and tolerability of lucerastat, and to determine its pharmacokinetic profile as single oral doses at different strengths.
The subjects were enrolled sequentially to five dose groups, starting with the lowest dose level. Subjects could participate in only one Group.
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
Drug: Lucerastat
Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
Drug: Lucerastat
These subjects received matching placebo administered orally in the morning of Day 1
Drug: Placebo
These subjects received matching placebo administered orally in the morning and in the evening of Day 1
Drug: Placebo
Hard gelatin capsule for oral administration containing lucerastat
Also known as: OGT-923, ACT-434964
Matching placebo capsules
Number of participants with Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation subject, which did not necessarily have a causal relationship with the treatment.
Time frame: From baseline up to 7 days post-administration
Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastat
Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving a single dose.
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastat
Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
Time to reach Cmax (tmax) of lucerastat after single ascending doses of lucerastat
tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving a single dose.
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
Time to reach Cmax (tmax) of lucerastat after two daily doses of lucerastat
tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
Area under the plasma concentration-time curves (AUC) of lucerastat after single ascending doses of lucerastat
AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving a single dose.
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
Area under the plasma concentration-time curves (AUC) of lucerastat after two daily doses of lucerastat
AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving lucerastat twice daily
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
Terminal elimination half-life (t1/2) of lucerastat after single ascending doses of lucerastat
t1/2 was calculated from the corresponding plasma concentrations-time curves for subjects receiving a single dose
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration
Terminal elimination half-life (t1/2) of lucerastat after two daily doses of lucerastat
t1/2 was calculated from the plasma concentrations-time curves for subjects receiving lucerastat twice daily
Time frame: PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration
Change from baseline in heart rate
Time frame: Up to 24 hours post administration
Change from baseline in blood pressure
Time frame: Up to 24 hours post administration
Change from baseline in electrocardiogram (ECG) variables
Time frame: Up to 24 hours post administration
Change from baseline in laboratory tests
Time frame: Up to 24 hours post administration
Plan to share: No
The record gives a start of Oct 2002, a primary completion of Dec 2002 and a completion of Dec 2002. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Migalastat
Idorsia Pharmaceuticals Ltd. →